Federal Register / Vol. 70, No. 23 / Friday, February 4, 2005 / Notices 6025

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Notice of Meeting: Secretary’s 

Advisory Committee on Genetics, 

Health, and Society 

Pursuant to Public Law 92–463, 

notice is hereby given of the sixth 

meeting of the Secretary’s Advisory 

Committee on Genetics, Health, and 

Society (SACGHS), U.S. Public Health 

Service. The meeting will be held from 

8:30 a.m. to 5:30 p.m. on February 28, 

2005 and 8:30 a.m. to 5 p.m. on March 

1, 2005 at the Bethesda North Marriott 

Hotel, 5701 Marinelli Road, North 

Bethesda, Maryland. The meeting will 

be open to the public with attendance 

limited to space available. The meeting 

will be webcast. 

The meeting is expected to include 

presentations and deliberations on 

several topics, including the following: 

a revised draft report with 

recommendations about coverage and 

reimbursement for genetic technologies 

and services; current and proposed 

efforts to understand gene-environment 

interactions through large population 

studies; the Committee’s efforts to 

explore stakeholder perspectives on the 

need for Federal legislation to prevent 

genetic discrimination in health 

insurance and employment; the 

recommendations of the Advisory 

Committee on Heritable Disorders and 

Genetic Diseases in Newborns and 

Children regarding the provision of 

screening, counseling and health care 

services for newborns and children 

having or at risk for heritable disorders; 

and efforts to improve the quality of 

laboratory testing for rare diseases. Time 

will be provided each day for public 

comments. 

Under authority of 42 U.S.C. 217a, 

Section 222 of the Public Health Service 

Act, as amended, the Department of 

Health and Human Services established 

SACGHS to serve as a public forum for 

deliberations on the broad range of 

human health and societal issues raised 

by the development and use of genetic 

technologies and, as warranted, to 

provide advice on these issues. The 

draft meting agenda and other 

information about SACGHS, including 

information about access to the webcast, 

will be available at the following Web 

site: http://www.od.nih.gov/oba/

sacghs.htm.

The Committee would welcome 

hearing from anyone wishing to provide 

public comment on any issue related to 

genetics, health and society. Individuals 

who would like to provide public 

comment or who plan to attend the 

meeting and need special assistance, 

such as sign language interpretation or 

other reasonable accommodations, 

should notify the SACGHS Executive 

Secretary, Ms. Sarah Carr, by telephone 

at 301–496–9838 or e-mail at 

sc112@nih.gov. The SACGHS office is 

located at 6705 Rockledge Drive, Suite 

750, Bethesda, MD 20892.

Dated: January 27, 2005. 

LaVerne Stringfield, 

Director, Office of Federal Advisory 

Committee Policy.

[FR Doc. 05–2128 Filed 2–3–05; 8:45 am] 

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Disorders; 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2) notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The purpose of this 

meeting is to evaluate requests for 

preclinical development resources for 

potential new therapeutics for type 1 

diabetes. The outcome of the evaluation 

will be a decision whether NIDDK 

should support the request and make 

available contract resources for 

development of the potential 

therapeutic to improve the treatment or 

prevent the development of type 1 

diabetes and its complications. The 

reserach proposals and the discussions 

could disclose confidential trade secrets 

or commercial property such as 

patentable material, and personal 

information concerning individuals 

associated with the proposed research 

projects, the disclosure of which would 

constitute a clearly unwarranted 

invasion of personal privacy.

Name of Committee: Type 1 Diabetes—

Rapid Access to Intervention Development 

Special Emphasis Panel, National Institute of 

Diabetes and Digestive and Kidney Diseases. 

Date: February 9, 2005. 

Time: 10 a.m.–2 p.m. 

Agenda: To evaluate requests for 

preclinical development resources for 

potential new therapeutics for type 1 diabetes 

and its complications. 

Place: 6707 Democracy Boulevard, 

Bethesda, MD 20892. (Telephone conference 

call.) 

Contact Person: Dr. Myrlene Staten, Senior 

Advisor, Diabetes Translation Research, 

Division of Diabetes, Endocrinology and 

Metabolic Diseases, NIDDK, NIH, 6707 

Democracy Boulevard, Bethesda, MD 20892–

5460. (301) 402–7886.

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.847, Diabetes, 

Endocrinology and Metabolic Research, 

93.848, Digestive Diseases and Nutrition 

Research; 98.849, Kidney Diseases, Urology 

and Hematology Research, National Institutes 

of Health, HHS.)

Dated: January 26, 2005 

LaVerne Y. Stringfield, 

Director, Office of Federal Advisory 

Committee Policy. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle.

[FR Doc. 05–2131 Filed 2–3–05; 8:45 am] 

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Library of Medicine; Notice of 

Meeting 

Pursuant to section 10(a) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the third meeting of 

the Commission on Systemic 

Interoperability. 

The meeting will be open to the 

public, with attendance limited to space 

available. Individuals who plan to 

attend and need special assistance, such 

as sign language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

The mission of the Commission on 

Systemic Interoperability is to submit a 

report to the Secretary of Health and 

Human Services and to Congress on a 

comprehensive strategy for the adoption 

and implementation of health care 

information technology standards that 

includes a timeline and prioritization 

for such adoption and implementation. 

In developing that strategy, the 

Commission will consider: (1) The costs 

and benefits of the standards, both 

financial impact and quality 

improvement; (2) the current demand 

on industry resources to implement the 

Medicare Prescription Drug, 

Improvement, and Modernization Act of 

2003 and other electronic standards, 

including HIPAA standards; and (3) the 

most cost-effective and efficient means 

for industry to implement the standards.

Name of Committee: Commission on 

Systemic Interoperability.